A CLEC9A nanobody, mRNA-LNP vaccine, its preparation method and application

By conjugating CLEC9A nanobody with mRNA-LNP, precise targeted delivery to dendritic cells was achieved, solving the problems of liver tropism and non-specific uptake of existing mRNA-LNP vaccines in vivo, and improving the efficacy of tumor immunotherapy.

CN123106903APending Publication Date: 2026-11-17GUANGZHOU FERMAT BIOTECHNOLOGY CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202611221398.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2026-08-12
Publication Date
2026-11-17

AI Technical Summary

Technical Problem

Existing mRNA-LNP vaccines exhibit liver tropism and are easily taken up non-specifically by macrophages in vivo, resulting in low uptake efficiency of antigen-presenting cells (especially dendritic cells), which affects the efficacy of tumor immunotherapy.

Method used

By conjugating CLEC9A nanobody with mRNA-LNP, the high affinity of CLEC9A nanobody specifically recognizes CLEC9A molecules, enabling active targeted delivery to dendritic cells, reducing non-specific accumulation in non-target tissues such as the liver, and improving the delivery efficiency of mRNA in the spleen and lymph nodes.

Benefits of technology

It significantly improved the delivery efficiency of mRNA in the spleen and lymph nodes, enhanced antigen cross-presentation and CD8+ T cell immune response, improved the efficacy of tumor immunotherapy, and reduced non-specific accumulation in non-target tissues such as the liver.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN123106903A_ABST
    Figure CN123106903A_ABST
Patent Text Reader

Abstract

This invention belongs to the field of biomedical technology, specifically relating to a CLEC9A nanobody, an mRNA-LNP vaccine, its preparation method, and its application. The complementarity-determining regions of the CLEC9A nanobody include CDR1, CDR2, and CDR3; the amino acids of CDR1 to CDR3 are shown in SEQ ID NO. 3 to SEQ ID NO. 5. After this nanobody is coupled to the surface of mRNA-LNP, the mRNA-LNP vaccine can more effectively promote antigen cross-presentation and significantly enhance CD8+. + T cell-mediated cellular immune responses and antigen-specific humoral immune responses have demonstrated superior tumor growth inhibition effects compared to unmodified LNPs in lung cancer xenograft models. Therefore, the CLEC9A nanobody of this invention provides a highly efficient targeting molecule for the precise delivery of mRNA-LNP vaccines, offering comprehensive advantages such as enhanced immunogenicity, reduced dosage, and fewer systemic side effects, demonstrating promising application prospects in the field of tumor immunotherapy.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention belongs to the field of biomedical technology, specifically relating to a CLEC9A nanobody, an mRNA-LNP vaccine, and their preparation methods and applications. Background Technology

[0002] Immunotherapy has emerged as one of the most promising treatment strategies in the field of cancer treatment. However, the overall objective response rate of widely used immune checkpoint inhibitors (ICIs) remains limited. Current technologies have revealed that ICI treatment can induce immune cell homeostasis disorders, thereby triggering immune-related adverse reactions and weakening its long-term clinical benefits to some extent. Developing novel immunotherapy strategies that combine higher safety and better efficacy has significant scientific and clinical value.

[0003] Tumor vaccines represent a crucial area of ​​development in immunotherapy. Based on their origin, tumor antigens are categorized into tumor-associated antigens (TAAs) and tumor-specific antigens (TSAs). TAAs are highly expressed in tumor tissues but also exist in normal tissues, and are easily limited by central and peripheral immune tolerance, resulting in limited clinical efficacy of early vaccines targeting gp100, MAGE-12, NY-ESO-1, etc. In contrast, TSAs (neoantigens) originate from gene mutations, possessing high tumor specificity and immunogenicity, and can induce stronger specific T-cell responses. Multiple clinical studies have confirmed their promising application prospects. Neoantigen vaccines include both shared and personalized types. Shared neoantigens can be developed into universal vaccines; for example, mutations such as KRAS and TP53 are common in various tumors, but their effectiveness is limited by patient genetic heterogeneity. With the development of next-generation sequencing and bioinformatics technologies, personalized neoantigens can be precisely identified through mutation screening, expression analysis, and HLA binding prediction, enabling the construction of peptide or mRNA vaccines and providing a technological foundation for precision tumor immunotherapy.

[0004] Compared to peptide vaccines, mRNA vaccines offer advantages such as shorter production cycles, rapid scalability, inherent adjuvant effects, and the ability to induce stronger and more durable immune responses. However, mRNA molecules are structurally unstable and susceptible to degradation by nucleases, necessitating encapsulation and protection by highly efficient delivery vectors to facilitate their entry into target cells and achieve effective expression. Lipid nanoparticles (LNPs) are currently the most mature mRNA delivery platform and have been successfully applied clinically. For example, mRNA vaccines developed by Pfizer / BioNTech and Moderna demonstrated significant protective effects during the COVID-19 pandemic. Nevertheless, the significant liver tropism exhibited by mRNA-LNP technology in vivo limits its widespread application in fields such as tumor immunology.

[0005] For tumor vaccines, the ability to induce a potent and durable protective immune response hinges on the antigen-presenting cells, particularly dendritic cells (DCs), and their capacity for antigen uptake, processing, and cross-presentation. During in vivo delivery, non-specific phagocytosis of mRNA vaccines by macrophages is a significant limiting factor affecting effective antigen distribution and immunization efficiency. Excessive macrophage clearance not only reduces vaccine transport efficiency to lymph nodes but may also weaken DC-mediated specific T cell activation. To improve DC uptake efficiency, researchers have attempted to introduce mannose ligands onto the surface of dendritic cells (LNPs) to promote their binding to mannose receptors on DC surfaces and mediate endocytosis. However, mannose receptors are also expressed on macrophages and endothelial cells, making highly specific targeting difficult. Therefore, providing a novel strategy for precisely delivering mRNA-LNP vaccines to dendritic cells is of significant clinical importance in overcoming current delivery technology bottlenecks and improving the efficacy of tumor immunotherapy. Summary of the Invention

[0006] The purpose of this invention is to provide a CLEC9A nanobody that solves the problems existing in the prior art.

[0007] The technical solution adopted in this invention is: The present invention provides a CLEC9A nanobody, wherein the complementarity-determining regions of the CLEC9A nanobody include CDR1, CDR2 and CDR3; The amino acid sequence of CDR1 is shown in SEQ ID NO.3; The amino acid sequence of CDR2 is shown in SEQ ID NO.4; The amino acid sequence of CDR3 is shown in SEQ ID NO.5.

[0008] Preferably, the sequence of the heavy chain variable region of the CLEC9A nanobody is shown in SEQ ID NO.2.

[0009] A second aspect of the present invention provides an mRNA-LNP vaccine comprising lipid nanoparticles and mRNA encapsulated therein, wherein the CLEC9A nanobody is coupled to the surface of the lipid nanoparticles.

[0010] A third aspect of this invention provides a method for preparing the mRNA-LNP vaccine, comprising the following steps: S1. Construct and prepare mRNA encoding the target antigen; S2. Ionized lipids, helper phospholipids, cholesterol, polyethylene glycol-modified lipids, and maleimide-functionalized lipids were dissolved in an organic solvent to prepare a lipid phase; the mRNA obtained in S1 was dissolved in a buffer solution to prepare an aqueous phase. S3. Mix the lipid phase with the aqueous phase to form lipid nanoparticles encapsulating mRNA; S4. Reduce the CLEC9A nanobody to release its thiol groups, and then couple it with the lipid nanoparticles encapsulating mRNA obtained in S3 to obtain the mRNA-LNP vaccine.

[0011] Preferably, the molar ratio of ionized lipids, cofactor phospholipids, cholesterol, polyethylene glycol-modified lipids, and maleimide-functionalized lipids is 50:10:38.5:1.25:0.25.

[0012] Preferably, the molar ratio of CLEC9A nanobody to lipid nanoparticles encapsulating mRNA is 1:1.

[0013] Preferably, the coupling conditions are 4°C for 12-18 hours.

[0014] Preferably, the volume ratio of the lipid phase to the aqueous phase is 1:3.

[0015] A fourth aspect of the present invention provides an application of the CLEC9A nanobody and / or the mRNA-LNP, characterized in that the application refers to the preparation of drugs for tumor immunotherapy.

[0016] Preferably, the tumor is lung cancer.

[0017] Compared with the prior art, the beneficial effects of the present invention are: This invention provides a CLEC9A nanobody, wherein the complementarity-determining region (CDR1), CDR2, and CDR3 are included; the amino acid composition of CDR1 is shown in SEQ ID NO.3; the amino acid composition of CDR2 is shown in SEQ ID NO.4; and the amino acid composition of CDR3 is shown in SEQ ID NO.5. This invention provides a novel CLEC9A nanobody structure. Through its unique complementarity-determining region, this nanobody can specifically recognize and bind to the CLEC9A molecule with picomolar affinity. This molecule is selectively highly expressed on classic dendritic cells, but almost not expressed on non-target cells such as macrophages and hepatocytes. This precise recognition characteristic fundamentally overcomes the off-target uptake problem caused by the wide distribution of mannose ligands, enabling the nanobody to actively target CLEC9A after being conjugated to the surface of mRNA-LNP. + The ability of dendritic cells (DCs) significantly reduces non-specific accumulation in non-target tissues such as the liver, while greatly improving the delivery efficiency of mRNA within DCs in the spleen and lymph nodes. Benefiting from this, the nanobody described in this invention, as a targeting molecule, not only solves the common defects of existing delivery systems—"strong non-specific clearance and low targeting precision"—but also facilitates efficient cross-presentation of subsequent antigens and CD8+. +The strong activation of T-cell immune responses lays the material basis for this, thus organically unifying precise delivery with immune enhancement, and providing a practical molecular tool for overcoming the delivery bottleneck of mRNA-LNP vaccines in tumor immunotherapy. Attached Figure Description

[0018] Figure 1 Affinity characterization and target binding ability evaluation of mCLEC9A 2A9 nanobodies; A: Biolayer interference (BLI) analysis of the purified 2A9 nanobody product; B: Flow cytometry detection of 2A9 and mCLEC9A + The binding ability of HEK-293T cells.

[0019] Figure 2 Evaluation of in vivo delivery efficiency of mCLEC9A 2A9 nanobody-functionalized mRNA-LNP; A: Quantitative analysis of bioluminescence imaging of isolated organs 4 h after intramuscular injection in mice; B and C represent, in order: EGFP in the spleen and lymph nodes. + Flow cytometry analysis of cell proportions. ** P < 0.01; ns, no significant difference.

[0020] Figure 3 This study aimed to enhance dendritic cell-targeted mRNA delivery and improve anti-tumor immune responses in a lung cancer model by targeting mCLEC9A-Nb-LNP.

[0021] A: Schematic diagram of animal experimentation process; B: Tumor growth curves in different groups of the LLC lung cancer xenograft model; C: Mouse weight analysis in each group; D~G: Flow cytometry detection of IFN-γ⁺CD8⁺ T, TNF-α⁺CD8⁺ T, IFN-γ⁺CD4⁺ T and TNF-α⁺CD4⁺ T cell subsets; H and I: CD11c, an activated subset of dendritic cells in the spleen + MHCII + and CD11c + CD86 + Proportional analysis. *P<0.05, **P<0.01; ns, no significant difference.

[0022] Figure 4 This study evaluated the in vivo biosafety of the mCLEC9A-Nb-LNP delivery system neoantigen vaccine. Serum biochemical parameters, including liver function-related indicators (ALT, AST, ALP, TP, ALB) and kidney function-related indicators (CREA, UREA), were measured. The results were not statistically significant. Detailed Implementation

[0023] The present invention will be further illustrated below with specific embodiments, but these embodiments do not limit the scope of the invention. Modifications or substitutions to the details and form of the technical solutions of the present invention may be made without departing from the spirit and scope of the invention, but all such modifications or substitutions fall within the protection scope of the present invention.

[0024] The inventive concept of this invention is as follows: To address the technical bottleneck of existing mRNA-LNP vaccines exhibiting liver tropism and being easily and non-specifically taken up by macrophages, resulting in low uptake efficiency by antigen-presenting cells (especially dendritic cells), this invention provides an active targeted delivery strategy based on CLEC9A nanobodies. This invention utilizes alpaca immunization and phage display technology to screen and obtain a CLEC9A nanobody (clone 2A9) with picomolar-level ultra-high affinity. This antibody can highly specifically recognize and bind to CLEC9A-positive dendritic cells. Conjugating this nanobody to the surface of mRNA-LNP conjugates the nanoparticles to actively target CLEC9A. + The ability of dendritic cells significantly enhances mRNA delivery efficiency in the spleen and lymph nodes, while reducing non-specific accumulation in non-target tissues such as the liver. As a result, this mRNA-LNP vaccine can more effectively promote antigen cross-presentation and significantly enhance CD8... + T-cell-mediated cellular immune responses and antigen-specific humoral immune responses demonstrated superior tumor growth inhibition effects compared to unmodified LNPs in lung cancer xenograft models, without causing significant systemic toxicity or organ damage. Overall, this invention utilizes "actively targeting DCs with nanobodies" as its core technology, coupling precise delivery with immune activation, providing a new solution for enhancing the immunogenicity and clinical translation of mRNA tumor vaccines.

[0025] To enable those skilled in the art to better understand and implement the technical solutions of the present invention, the present invention will be further described below with reference to specific embodiments. In the description of the present invention, unless otherwise specified, all reagents used are commercially available, and all methods used are conventional techniques in the art.

[0026] The list of abbreviations for this invention is shown in Table 1.

[0027] Table 1. List of abbreviations for this invention Example 1 The specific preparation method of a CLEC9A nanobody is as follows: 1. Preparation methods of immune proteins.

[0028] The mCLEC9A protein, a fusion of the extracellular domain of mouse C-type lectin domain family 9 member A (mCLEC9A) with a human IgG1 Fc fragment, was used as an immunogen. The mCLEC9A ECD sequence (amino acid sequence shown in SEQ ID NO.1) was linked to the N-terminus of the human IgG1 Fc fragment via a (G4S)2 linker peptide, and a His tag sequence was further linked to the C-terminus of the IgG1 Fc fragment for subsequent purification of the expression product. To achieve secretory expression, an IL-2 signal peptide sequence was introduced at the N-terminus of the mCLEC9A ECD. The fusion protein expression sequence was constructed into the pcDNA3.1(+) expression vector and transiently transfected into Freestyle 293F cells using PEI transfection reagent. Seven days after transfection, the culture supernatant was collected, cell debris was removed by centrifugation, and the recombinant protein was purified by NTA-His affinity chromatography (pH 7.4).

[0029] SEQ ID NO.1: KFFQVSSLVLEQQERLIQQDTALVNLTQWQRKYTLEYCQALLQRSLHSGSDCSPCPHNWIQNGKSCYYVFERWEMWNISKKSCLKEGASLFQIDSKEEMEFISSIGKLKGGNKYWVGVFQDGISGSWFWEDGSSPLSDLLPAERQRSAGQICGYLKDSTLISDKCDSWKYFICEKKAFGSCI.

[0030] 2. Methods for constructing alpaca immune and nanobody libraries.

[0031] Take 200 μg of the recombinant protein obtained above, dilute it to 500 μL with PBS, and then mix it with Gerbu LQ#3000 at a volume ratio of 1:1 to form an immunoassay. Immunize alpacas using the immunoassay, once every two weeks. After three immunizations, collect 100 mL of peripheral blood from the alpacas for the isolation of peripheral blood mononuclear cells (PBMCs). Perform total RNA extraction, cDNA synthesis, and two rounds of PCR amplification on the obtained PBMCs to obtain the variable domain (VHH) fragment of the heavy chain antibody.

[0032] The VHH cDNA was purified by agarose gel electrophoresis and cloned into the SfiI restriction site of the phage vector pADL-23c. Subsequently, the obtained recombinant pADL-23c vector was transformed into electrocompetent Escherichia coli TG1 cells to construct a VHH nanobody library. Finally, the TG1 library was infected with M13K07 helper phage to obtain a phage library displaying VHH.

[0033] 3. Nanobody screening.

[0034] VHH phage targeting mCLEC9A ECD was enriched using two rounds of biopanning with 50 nM and 5 nM biotinylated mCLEC9A ECD, respectively, and captured using Dynabeads™ M-280. The degree of enrichment after each round of screening was assessed by 10-fold serial dilution plate culture.

[0035] After the second round of screening, 94 monoclonal phage particles were selected. VHH display phages were recovered by infection with M13K07 helper phage, and their binding ability to mCLEC9A ECD was detected using ELISA. In the experiment, mCLEC9A ECDs were immobilized on 96-well plates, and the binding of phage clones was detected. The bound phages were detected using HRP-labeled anti-M13 antibody.

[0036] 4. Biological layer interference.

[0037] The binding affinity between high-affinity VHH and mCLEC9A ECD antigen was determined using the Fortebio Octet system. First, the streptavidin biosensor was equilibrated in PBST buffer for 10 min. Then, the sensor was exposed to diluted biotinylated mCLEC9A ECD protein, bound, and then placed back into PBST buffer. Subsequently, the sensor was reacted with VHH samples diluted at different concentrations. The binding rate (Kon), dissociation rate (Koff), and dissociation constant (KD) were analyzed using ForteBioData Analysis 12.0 software. After screening, the nanobody with the strongest affinity was obtained, designated 2A9.

[0038] 5. Preparation method of nanobody protein.

[0039] The nanobody 2A9, which had been screened for the strongest affinity, was expressed in the pADL-23c vector. The plasmid was transformed into the WK6 strain of *E. coli* and induced overnight by 1 mM IPTG at 20 °C. Periplasmic extracts were prepared by osmotic shock chromatography and purified by immobilized metal affinity chromatography (IMAC) on an AKTXpress automated system. The purified extract was then gel-filtered using a Superdex 75 10 / 300GL column with phosphate-buffered saline (DPBS, pH 7.4) as the buffer.

[0040] 6. Preparation method of nanobody 2A9-Fc.

[0041] The 2A9-Fc fusion protein expression sequence was constructed into the pcDNA3.1(+) expression vector and transiently transfected into Freestyle 293F cells using PEI transfection reagent. Seven days after transfection, the culture supernatant was collected, cell debris was removed by centrifugation, and the recombinant protein was purified using AmMag™ Protein A, followed by gel filtration purification in DPBS (pH 7.4) buffer.

[0042] The heavy chain variable region of 2A9 is shown in SEQ ID NO.2, and the complementarity determination regions CDR1~CDR3 determined by IMGT are shown in SEQ ID NO.3~SEQ ID NO.5.

[0043] SEQ ID NO.2: DVQLQESGGGLVQPGGSLRLSCAASGFTFGNAIMTWHRQAPGKQRELVASITSITYNAEYVDSVKGRFTISRDNDKHMVYLQMNSLKPEDTAVYYCNTFPMIGNYWGQGTQVTVSS.

[0044] SEQ ID NO.3: GFTFGNAI.

[0045] SEQ ID NO.4: ITSITYNA.

[0046] SEQ ID NO.5: NTFMIGNY.

[0047] To systematically evaluate the binding affinity between candidate nanobodies and the mCLEC9A antigen, this invention employed a biomolecular interaction analysis system to detect the affinity of different cloned nanobodies. The results showed that all candidate clones exhibited varying degrees of mCLEC9A binding activity, with clone 2A9 exhibiting the best binding performance. Kinetic analysis indicated that the dissociation constant (KD) between 2A9 and the mCLEC9A antigen was 3.2 pM, suggesting extremely high antigen affinity and strong targeting recognition ability. Figure 1 Based on this, to further improve the stability of the nanobody, prolong its in vivo half-life, and facilitate subsequent detection and application, this invention constructed a 2A9-Fc fusion protein, which is a fusion expression of a 2A9 nanobody and a human IgG1 Fc fragment. Subsequently, the binding ability of 2A9-Fc to mCLEC9A positive cells was detected by flow cytometry. The results showed that 2A9-Fc could specifically recognize and bind to HEK-293T cells expressing mCLEC9A, while no obvious non-specific binding signal was observed in negative control cells. Figure 1 B).

[0048] Example 2 An application of a CLEC9A nanobody is as follows: 1. This embodiment provides an mRNA-LNP vaccine based on the CLEC9A nanobody prepared in Example 1. The specific preparation method is as follows: S1, mRNA construction and synthesis.

[0049] A neoantigen sequence from the LLC1 mouse lung cancer cell line (amino acid sequences shown in SEQ ID NO. 6 and SEQ ID NO. 7) was inserted into an mRNA platform backbone vector (T7-5'UTR-CDS-3'UTR-polyA). The neoantigen sequence consists of a set of synthetic DNA fragments encoding five potential novel epitopes, each encoding 27 amino acids, with a mutation site located at position 14. The fragments are linked by non-immunogenic glycine / serine linker peptides, with the middle linker peptide being GGSGGGGGSGG and the terminal linker peptide being GGSLGGGGSG. The N-terminus of the neoantigen sequence contains an SP signal peptide (amino acid sequence shown in SEQ ID NO. 8), and the C-terminus contains an MITD domain (amino acid sequence shown in SEQ ID NO. 9) to optimize antigen presentation into the MHC I and MHC II pathways. This sequence was cloned into the pUC19 vector.

[0050] SEQ ID NO.6, the amino acid sequence of the new MHC-I class of antigens from the LLC1 mouse lung cancer cell line: MRVTAPRTLILLLSGALALTETWAGSPIEVNLFGLINVTPNMLPLVKKARGRVGGSGGGGSGGCAVNEKINRVVFVWNFLRVNTLSMKLLGGSGGGGSGGYSRTDSVIRLLSALLRVSEVESRAIRAGGSG GGGSGGRRAKKGDLKVSIHHMEMERIRYVLSSYGGSLGGGGSGNVIHMLESFTFRNNVCMAFELLSIDLYHHHHHHIVGIVAGLAVLAVVVIGAVVATVMCRRKSSGGKGGSYSQAASSDSAQGSDVSLTA.

[0051] SEQ ID NO.7, amino acid sequence of the new MHC-II antigen from the LLC1 mouse lung cancer cell line: MRVTAPRTLILLLSGALALTETWAGSTKTELELALSPIHYSSAIPAAGSNQVTGGSGGGGSGGLEKIQEELEFQPPEVLSLEDTDVANGMGGSGGGGSGGEPEFYLISSFWPSFPSNMDAAYEVTNRGGSG GGGSGGKNSRNGGDSEAIPFTSPNVVKFSTPPTGGSLGGGGSGHSGAEQYFKEWFSIPANLHGIILPRLSHHHHHHIVGIVAGLAVLAVVVIGAVVATVMCRRKSSGGKGGSYSQAASSDSAQGSDVSLTA.

[0052] SEQ ID NO.8, SP signal peptide amino acid sequence: MRVTAPRTLILLLSGALALTETWAGS.

[0053] SEQ ID NO.9, MITD domain amino acid sequence: IVGIVAGLAVLAVVVIGAVVATVMCRRKSSGGKGGSYSQAASSDSAQGSDVSLTA.

[0054] SEQ ID NO.10: GGSGGGGGSGG.

[0055] SEQ ID NO.11: GGSLGGGGSG.

[0056] Plasmid DNA was purified using the PureLink™ HiPure Plasmid DNA Purification Kit (CAT.K210004, Thermo Fisher Scientific) and then linearized using XhoI restriction endonuclease. Subsequently, neoantigen mRNA was synthesized via in vitro transcription, performed according to the manufacturer's instructions using the T7 HighYield RNA Synthesis Kit (AGCN) (CAT.10110N, Jiangsu Synthgene Biotechnology). After transcription, DNase I was added to the reaction mixture, and the mixture was incubated at 37°C for 30 min to digest the DNA template. The resulting mRNA was further purified by column centrifugation. RNA quality was assessed by agarose gel electrophoresis, and the final concentration was determined using a NanoDrop spectrophotometer.

[0057] S2 and LNP preparation.

[0058] The lipids used to prepare mRNA-LNPs were ionized lipids (SM-102), DSPC, cholesterol, DMG-PEG2000, and DSPE-PEG-Maleimide, with a molar ratio of 50:10:38.5:1.25:0.25. The LNPs prepared according to this formulation had an N / P ratio of 6.3, where "N" represents ionizable amino groups and "P" represents phosphate groups in the mRNA backbone.

[0059] Preparation of the lipid phase: Take SM-102, DSPC, cholesterol, DMG-PEG2000 and DSPE-PEG-Maleimide according to the above molar ratio, add them to a 15mL centrifuge tube, and then use anhydrous ethanol to make up the total volume of the lipid mixture to 3.75mL.

[0060] Preparation of the aqueous phase: 1.5 mg of purified mRNA was transferred to a 15 mL centrifuge tube, and then the total volume of the mRNA solution was brought up to 11.25 mL using citrate buffer at pH 3.0.

[0061] Finally, the lipid phase and the aqueous phase of mRNA were mixed at a volume ratio of 1:3 using a microfluidic chip. The resulting LNP-mRNA was dialyzed overnight in PBS at pH 7.2 using Slide-A-Lyzer and concentrated using Amicon Ultra ultrafiltration centrifuge tubes (Merck).

[0062] S3, Nb-LNP coupling.

[0063] The mCLEC9A nanobody 2A9 was first reduced using TCEP (CAT.ST045, Beyotime) at room temperature for 60 min. TCEP was then removed via a 3 kDa ultrafiltration centrifuge tube, and the antibody was resuspended in 100 μL of DPBS. The product obtained in step S2 was mixed with the reduced 2A9 antibody at a 1:1 molar ratio, and the mixture was reacted at room temperature for 1 h, followed by overnight reaction at 4°C to complete conjugation. Unbound nanobodies were removed via a 100 kDa molecular weight cutoff centrifuge filter to obtain the mRNA-LNP vaccine, designated as mCLEC9A-Nb-LNP.

[0064] 2. The efficacy of the mCLEC9A-Nb-LNP vaccine obtained above was verified.

[0065] (1) Construct a mouse tumor model.

[0066] A tumor model was established by subcutaneous injection of LLC cells into 8-week-old male C57BL / 6 mice. Each mouse was inoculated with 1×102 LLC cells. 6Cells were collected. Animals were housed in an SPF-grade animal facility with 70% humidity and a temperature of 22±1℃, using a 12-hour light-dark cycle. Mice were fed normally for 10 days after LLC cell inoculation. Before treatment, the mCLEC9A-Nb-LNP vaccine was diluted to 200 μg / mL with PBS. Tumor-bearing mice received the mCLEC9A-Nb-LNP vaccine via intramuscular injection on days 13 and 20 after tumor cell inoculation. The dose was 10 μg mRNA per mouse, corresponding to an injection volume of 50 μL per mouse. Tumor size was measured every 3 days using electronic calipers and calculated according to the formula V(mm). 3 The tumor volume is calculated as (length × width²) ÷ 2. According to animal welfare standards, a tumor is considered a tumor if the mouse's body weight decreases by 20% from its initial weight, or if the tumor volume exceeds 2000 mm². 3 At that time, the mice were euthanized.

[0067] (2) The mCLEC9A-Nb-LNP vaccine significantly enhances the delivery efficiency of mRNA to dendritic cells.

[0068] To evaluate the targeted delivery performance of mCLEC9A nanobody-modified LNP (mCLEC9A-Nb-LNP) in vivo, C57BL / 6 mice were intramuscularly injected with luciferase-labeled mCLEC9A-Nb-LNP, followed by in vivo bioluminescence imaging analysis. Results are as follows: Figure 2 As shown, Unmodified-LNP is the product of S2 in the above preparation process.

[0069] Figure 2 The results showed that, compared with unmodified LNP, mCLEC9A-Nb-LNP significantly reduced non-specific accumulation in the liver, while its overall bioluminescent signal intensity was significantly enhanced, suggesting that its in vivo distribution is more conducive to antigen expression and immune activation. Figure 2 (A). Subsequently, the uptake efficiency of mRNA encoded by EGFP mRNA-LNP was further evaluated by immune cells in the spleen and lymph nodes. Flow cytometry analysis showed that, compared with Unmodified-LNP, the proportion of EGFP⁺ DCs in the spleen and lymph nodes was significantly increased after treatment with mCLEC9A-Nb-LNP (A). Figure 2 (B and C), indicating that it significantly enhances the targeted delivery capability to CLEC9A⁺DC. Based on the preliminary confirmation that the LNP modified with mCLEC9A nanobody can significantly enhance the targeted delivery and uptake efficiency of mRNA to dendritic cells, its immune function conversion effect in an in vivo tumor model was further evaluated.

[0070] (3) mCLEC9A-Nb-LNP delivered mRNA vaccine significantly enhanced anti-tumor immune response in lung cancer model.

[0071] To evaluate whether mCLEC9A-Nb-LNP can enhance the anti-tumor effect of mRNA tumor vaccines, this invention uses the mouse lung cancer cell line LLC to construct a syngeneic tumor model. First, based on whole-exome sequencing and transcriptome sequencing data, combined with machine learning algorithms, a tumor mutation profile and candidate neoantigen library of LLC were constructed. Considering parameters such as MHC binding affinity and expression abundance, candidate novel epitopes of MHC class I restriction and MHC class II restriction were screened to construct a neoantigen mRNA vaccine for in vivo anti-tumor research. Syngeneic xenograft tumor models were established by subcutaneously inoculating LLC cells into C57BL / 6 mice, and on days 3 and 7 after tumor establishment, the neoantigen mCLEC9A-Nb-LNP was administered for immunization. Figure 3 The results showed that, compared with the Unmodified LNP group, the mCLEC9A-Nb-LNP vaccine exhibited a significantly enhanced tumor growth inhibition effect (A). Figure 3 (B); Weight monitoring results showed that on day 25, the control group experienced a slight weight gain due to the increase in tumor volume, indicating that the vaccine intervention did not cause significant systemic toxicity. Figure 3 (C). Among them, Unmodified-LNP is the product of S2 in the above preparation process.

[0072] To systematically evaluate the level of T-cell immune response dependent on antitumor efficacy, flow cytometry was used to detect the proportion of effector T cells in the spleen and lymph nodes of immunized mice. The results showed that, compared with the PBS control, both Unmodified-LNP and mCLEC9A-Nb-LNP significantly amplified IFN-γ⁺CD8⁺, TNF-α⁺CD8⁺, and IFN-γ⁺CD4⁺ T cell subsets. The mCLEC9A-Nb-LNP group induced a stronger cytokine response in all detected subsets. Figure 3 (D~F). Notably, almost no significant expansion of TNF-α⁺CD4⁺ T cells was observed in the Unmodified-LNP group, while the mCLEC9A-Nb-LNP group significantly increased the proportion of this subset in the spleen (D~F). Figure 3 The presence of G suggests that it has a significant advantage in enhancing the activation of helper T cell function.

[0073] To further verify whether the enhanced T cell response described above originates from the targeted delivery of mRNA to dendritic cells (DCs) and its maturation-promoting effect, the expression levels of DC surface activation markers in the spleen of immunized mice were examined. Figure 3The results showed that, compared with Unmodified LNP, the mCLEC9A-Nb-LNP vaccine significantly improved DC maturation, with a marked increase in the proportions of CD11c⁺MHCII⁺ and CD11c⁺CD80⁺CD86⁺ cells. These results preliminarily indicate that mCLEC9A-Nb-LNP can enhance DC activation and antigen presentation through precise targeted delivery, thereby driving a more potent anti-tumor T-cell immune response. To systematically evaluate the translational application potential of this delivery system, a comprehensive in vivo biosafety assessment of its neoantigen vaccine was conducted.

[0074] (4) In vivo biosafety evaluation of the neoantigen vaccine delivered by the mCLEC9A-Nb-LNP delivery system.

[0075] In terms of safety evaluation, hematoxylin and eosin (H&E) staining was used for histopathological analysis of major organs such as the heart, liver, spleen, lungs, and kidneys. Results showed that the structures of all organs were intact, with no obvious inflammatory infiltration, tissue necrosis, or structural abnormalities. Simultaneously, liver and kidney function and overall toxicity levels were assessed through blood biochemical index testing. Results indicated no significant differences in organ function indicators between the immunized group and the control group. Figure 4 The above results indicate that, under the prescribed dosage and immunization schedule, this delivery system did not cause significant systemic adverse reactions and has good biocompatibility.

[0076] The technical features of the above embodiments can be combined in any way. For the sake of brevity, not all possible combinations of the technical features in the above embodiments are described. However, as long as there is no contradiction in the combination of these technical features, they should be considered to be within the scope of this specification.

[0077] The embodiments described above are merely examples of several implementations of the present invention, and while the descriptions are relatively specific and detailed, they should not be construed as limiting the scope of the invention. It should be noted that those skilled in the art can make various modifications and improvements without departing from the concept of the present invention, and these modifications and improvements all fall within the scope of protection of the present invention.

Claims

1. A CLEC9A nanobody, characterized in that, The complementarity-determining regions of the CLEC9A nanobody include CDR1, CDR2, and CDR3; The amino acid sequence of CDR1 is shown in SEQ ID NO.3; The amino acid sequence of CDR2 is shown in SEQ ID NO.4; The amino acid sequence of CDR3 is shown in SEQ ID NO.

5.

2. The CLEC9A nanobody as described in claim 1, characterized in that, The sequence of the heavy chain variable region of the CLEC9A nanobody is shown in SEQ ID NO.

2.

3. An mRNA-LNP vaccine, characterized in that, The mRNA-LNP vaccine comprises lipid nanoparticles and mRNA encapsulated therein, wherein the surface of the lipid nanoparticles is coupled with the CLEC9A nanobody of claim 1.

4. The method for preparing the mRNA-LNP vaccine as described in claim 3, characterized in that, The steps are as follows: S1. Construct and prepare mRNA encoding the target antigen; S2. Ionized lipids, helper phospholipids, cholesterol, polyethylene glycol-modified lipids, and maleimide-functionalized lipids were dissolved in an organic solvent to prepare a lipid phase; the mRNA obtained in S1 was dissolved in a buffer solution to prepare an aqueous phase. S3. Mix the lipid phase with the aqueous phase to form lipid nanoparticles encapsulating mRNA; S4. Reduce the CLEC9A nanobody to release its thiol groups, and then couple it with the lipid nanoparticles encapsulating mRNA obtained in S3 to obtain the mRNA-LNP vaccine.

5. The preparation method according to claim 4, characterized in that, The molar ratio of ionized lipids, cofactor phospholipids, cholesterol, polyethylene glycol-modified lipids, and maleimide-functionalized lipids was 50:10:38.5:1.25:0.

25.

6. The preparation method according to claim 4, characterized in that, The molar ratio of CLEC9A nanobody to lipid nanoparticles encapsulating mRNA is 1:

1.

7. The preparation method according to claim 4, characterized in that, The coupling conditions are 4℃ for 12-18 hours.

8. The preparation method according to claim 4, characterized in that, The volume ratio of the lipid phase to the aqueous phase is 1:

3.

9. The application of the CLEC9A nanobody of claim 1 and / or the mRNA-LNP of claim 3, characterized in that, The application refers to the preparation of drugs for tumor immunotherapy.

10. The application as described in claim 9, characterized in that, The tumor is lung cancer.